December 4th 2024
Researchers observe significant shifts in payer preferences for originator vs biosimilar products from 2017 to 2022, revealing growing payer interest in multiple product options, alongside the increasing market share of biosimilars, which contributed to notable reductions in both average sales prices and wholesale acquisition costs.
Dr Ivo Abraham Column: It's What We Do With the Savings—Economics and Equity
August 30th 2022Ivo Abraham, PhD, chief scientist of Matrix45 and a professor at the University of Arizona, describes the pharmacoeconomics of biosimilars and the savings potential for practices and payers if they prioritize greater biosimilar adoption.
Vizient Survey Reveals Provider Motivations for Choosing Biosimilar Over Humira
August 23rd 2022Vizient’s 2022 Biosimilar Survey found that health care organizations consider interchangeable designations to be very important in prescription decision-making, signaling the interchangeability could play a big role in the adoption of adalimumab biosimilars.
Biosimilar Infliximab Deemed Safe, Effective in Pediatric Patients With IBD
August 22nd 2022Researchers found that an infliximab biosimilar was as safe and effective as the reference product (Remicade) in pediatric patients with inflammatory bowel disease. However, more studies on adalimumab biosimilars in pediatric patients are needed.
Study: Biosimilar Uptake, Rather Than Competition, Will Influence Price Decreases
August 15th 2022Researchers found that the percentage of biosimilar uptake is a better predictor of whether prices of biologics will significantly decrease, refuting the argument that more biosimilars for a single reference product will have the biggest impact.
Vizient Market Outlook Report Predicts Trends for Adalimumab Biosimilars in 2023
August 2nd 2022Vizient’s Pharmacy Market Outlook report offers predictions on how the emergence of adalimumab biosimilars in 2023 will affect the biosimilar industry and what actions should be taken in advance to ensure biosimilar adoption.
Contributor: Good Bait and Fair Switch—Biosimilar Interchangeability, Substitution, and Choice
July 11th 2022Ivo Abraham, PhD, chief scientist of Matrix45 and a member of The Center for Biosimilars® Advisory Board, explains the difference between biosimilar interchangeability and substitution and weighs in on whether switching studies are necessary.
Survey: Most Patients Received Inadequate Information About Switching to a Trastuzumab Biosimilar
July 9th 2022A survey study found that many patients with breast cancer reported receiving inadequate information regarding switching from Herceptin to a trastuzumab biosimilar, with some patients reporting that they were never told a switch occurred or what a biosimilar was.
Medicines for Europe Recommends Off-Patent Drugs to Strengthen European Health Systems
July 5th 2022During its annual conference in Sitges, Spain, Medicines for Europe recommended policy reforms for strengthening European health systems, including the use of off-patent medications like biosimilar and generic drugs.
How Will Payers Manage Multiple Adalimumab Biosimilars? Jeffrey Casberg Explains
June 22nd 2022Jeffrey Casberg, vice president of pharmacy at IPD Analytics, discussed the different options that payers have to manage the growing number of biosimilars referencing Humira (adalimumab) that are expected to enter the market in 2023 and beyond.
ASCO Studies Assess Biosimilar Substitution, Adoption in Oncology Practices
June 16th 2022Abstracts from the American Society of Clinical Oncology (ASCO) annual meeting took a look at the impact biosimilar substitution and increased biosimilar adoption had on spending within practices participating in value-based payment models and the Oncology Care Model.
Gillian Woollett Catalogues How Conversations Surrounding Biosimilars Evolved
June 12th 2022Gillian Woollett, MA, DPhil, vice president and head of regulatory strategy and policy at Samsung Bioepis, outlines how concerns over the safety and efficacy of biosimilars has shifted and what new concerns the industry is focusing on.
Ryan Haumschild, PharmD, Advises Practices, Health Systems to Prep for Interchangeable Biosimilars
June 5th 2022Ryan Haumschild, PharmD, MS, MBA, from Emory Healthcare and Winship Cancer Institute, gives an overview of what practices and health systems need to prepare for as more interchangeable biosimilars enter the US market.
Contributor: No Good Deed Goes Unpunished—How PBM Mandates Increase Practice Variability
May 17th 2022Jeff Patton, MD, CEO and board member at OneOncology, dived into the controversial role that pharmacy benefit managers (PBMs) play in formulary decision-making and how PBMs impact biosimilar utilization.
Conference Posters Highlight Real-world Trends of Biosimilars, Reclassified Biologics
May 14th 2022Posters from the Academy of Managed Care Pharmacy (AMCP)’s annual meeting examined the real-world patterns of biosimilar utilization and the impact of products that have been reclassified as biologics on Medicaid spending.
Health IT for Biosimilars Spotlight: Cardinal Health's Decision Pathway
May 10th 2022Amy Valley, vice president of clinical strategy and technology solutions at Cardinal Health, details the company's Decision Pathway, a health information technology (IT) tool that can assist practices with prescribing patients the lowest-cost product, including biosimilars.
Given Public Concerns, Canadian Policy Makers Should Be Cautious When Making New Biosimilar Policies
May 5th 2022A report on biosimilar uptake and existing policies signals that policy makers should proceed with caution when establishing new policies to boost biosimilar utilization and savings, as many patients and providers still have concerns on their usage.
Opinion: Efforts to Improve Biosimilars Education Are a Start, but Payer Policies Must Catch Up
May 2nd 2022Despite improvements in biosimilar education efforts for future health care professionals, payer policies need a major revamp to ensure that biosimilar use is encouraged, according to Pfizer's Mike Gladstone.
Opinion: Biosimilar Adoption Will Help Achieve a Bipartisan Goal
April 25th 2022Biosimilars provide significant savings and encourages competition in the biopharmaceutical marketplace but the United States needs to do more to empower uptake and address adoption barriers, according to Robert Popovian PharmD, MS.
Pegfilgrastim Biosimilars Provide Clinical, Economic Benefits to Prevent Febrile Neutropenia
April 18th 2022An analysis of real-world dosing and effectiveness of pegfilgrastim biosimilars found the clinical benefits of preventing febrile neutropenia in patients with intermediate to high risk come at acceptable financial costs compared with filgrastim biosimilars.
Dr Edward Arrowsmith Discusses Clinical Pathways, Biosimilars in Ensuring Quality of Care
April 5th 2022Edward Arrowsmith, MD, discussed his recent paper on the use of clinical pathways for specific cancer types and how biosimilar development can help ensure quality of care for patients with limited therapeutic options.
Dr Chelsee Jensen and Dr Eric Tichy Discuss the Mayo Clinic's Success With Biosimilar Adoption
April 3rd 2022Chelsee Jensen, PharmD, and Eric Tichy, PharmD, MBA, who coauthored a paper on the Mayo Clinic's success with implementing biosimilars, discuss their study and how their practice is expected to evolve to improve its approach.
Jeffery Casberg Previews His Presentations at AMCP 2022
March 27th 2022Jeffrey Casberg, vice president of pharmacy at IPD Analytics, previews his sessions about the new and emerging pharmaceutical products coming down the pipeline at the upcoming Academy of Managed Care Pharmacy (AMCP) annual meeting.